Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: A phase III clinical trial

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Dollinger, Matthias M ^a   Lautenschlaeger, Christine ^a   Lesske, Joachim ^a   Tannapfel, Andrea ^b   Wagner, Anna Dorothea ^a   Schoppmeyer, Konrad ^c   Nehls, Oliver ^d   Welker, Martin Walter ^e   Wiest, Reiner ^f   Fleig, Wolfgang E ^a,g  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^g UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINOTRANSFERASE; CREATININE; DOXORUBICIN; PLACEBO; PLATINUM DERIVATIVE; SOMATOSTATIN; TAMOXIFEN; THYMOSTIMULIN; UREA; INTERFERON INDUCING AGENT; THYMUS EXTRACT;

ABDOMINAL PAIN; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASCITES; BLOOD TOXICITY; BRAIN DISEASE; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INFECTIOUS COMPLICATION; INJECTION SITE REACTION; KARNOFSKY PERFORMANCE STATUS; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL TIME; TREATMENT RESPONSE; UREA BLOOD LEVEL; ADOLESCENT; COMPARATIVE STUDY; DISEASE COURSE; FOLLOW UP; LIVER TUMOR; METASTASIS; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON INDUCERS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PLACEBOS; PROSPECTIVE STUDIES; SURVIVAL RATE; THYMUS EXTRACTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956520653     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-457     Document Type: Article

References (26)

1. Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16. 10.1053/j.gastro.2004.09.011, 15508102.
2. Burroughs A, Hochhauser D, Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004, 5:409-418. 10.1016/S1470-2045(04)01508-6, 15231247.
3. Beaugrand M, N'kontchou G, Seror O, et al. Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis 2005, 25:201-211. 10.1055/s-2005-871199, 15918148.
4. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002, 35:519-524. 10.1053/jhep.2002.32089, 11870363.
5. Fleig WE, Lesske J. Hepatocellular carcinoma: Primary and secondary prophylaxis as well as medical therapy. Chir Gastroenterol 2003, 19:247-252.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. NEJM 2008, 359:378-390. 10.1056/NEJMoa0708857, 18650514.
7. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711. 10.1093/jnci/djn134, 18477802.
8. Geissler M, Mohr L, Ali MY, et al. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma. Z Gastroenterol 2003, 41:1101-1110. 10.1055/s-2003-44304, 14648380.
9. Dechant KL, Bryson HM. Thymostimulin: a review of its pharmacology and prospective role in immunotherapy. Clin Immunother 1994, 1:378-398.
10. Balch G, Izzo F, Chiao P, et al. Activation of human Kupffer cells by thymostimulin (TP-1) to produce cytotoxicity against human hepatocellular cancer. Ann Surg Oncol 1997, 4:149-155. 10.1007/BF02303798, 9084852.
11. Palmieri G, Biondi E, Morabito A, et al. Thymostimulin treatment of hepatocellular carcinoma on liver cirrhosis. Int J Oncol 1996, 8:827-832.
12. Dollinger MM, Behrens CM, Lesske J, et al. Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. BMC Cancer 2008, 8:72. 10.1186/1471-2407-8-72, 2323008, 18366627.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655. 10.1097/00000421-198212000-00014, 7165009.
15. Heffernan N, Cella D, Webster K, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: The Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep) questionnaire. J Clin Oncol 2002, 20:2229-2239. 10.1200/JCO.2002.07.093, 11980994.
16. Macchiarini P, Danesi R, Del Tacca M, et al. Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients. Anticancer Res 1989, 9:193-6.
17. Goldstein AL, Garaci E. Preface: The "New Medicines". Ann NY Acad Sci 2007, 1112:xi-xii.
18. Rustigi VK. Thymalfasin for the Treatment of Chronic Hepatitis C Infection. Ann NY Acad Sci 2007, 1112:357-367. 10.1196/annals.1415.034, 17600289.
19. Garaci E, Favalli C, Pica F, et al. Thymosin Alpha 1: From Bench to Bedside. Ann NY Acad Sci 2007, 1112:225-234. 10.1196/annals.1415.044, 17600290.
20. Moody TW. Thymosin α1 as a Chemopreventive Agent in Lung and Breast Cancer. Ann NY Acad Sci 2007, 1112:297-304. 10.1196/annals.1415.040, 17567944.
21. German Federal Statistical Office Chapter 5.22 Chronische Leberkrankheit und -zirrhose. Bundesgesundheitsbericht für Deutschland 1998, (accessed January 10, 2010), German Federal Statistical Office., http://www.gbe-bund.de
22. Stefanini GF, Foschi FG, Castelli E, et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterol 1998, 45:209-15.
23. Gish R, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatology International 2009, 3:480-489.
24. Romani L, Bistoni F, Montagnoli C, et al. Thymosin α1: An Endogenous Regulator of Inflammation, Immunity, and Tolerance. Ann NY Acad Sci 2007, 1112:326-338. 10.1196/annals.1415.002, 17495242.
25. Tortorella C, Ottolenghi A, Moretti AM, et al. Thymostimulin administration modulates polymorph metabolic pathway in patients with chronic obstructive pulmonary disease. Immunopharmacol Immunotoxicol 1992, 14:421-437. 10.3109/08923979209005402, 1325490.
26. Ikemoto S, Sugimura K, Kamizuru M, et al. Protective effect of thymosin fraction 5 in animals with experimentally induced uremia. Clin Exp Nephrol 2000, 4:215-219.